miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma [0.03%]
microRNA-22通过调节基因表达抑制透明细胞肾癌的侵袭并预测患者的预后
Xue Gong,Hongjuan Zhao,Matthias Saar et al.
Xue Gong et al.
Background: Clear cell renal cell carcinoma (ccRCC) is molecularly diverse and distinct molecular subtypes show different clinical outcomes. MicroRNAs (miRNAs) are essential components of gene regulatory networks and play...
Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249) [0.03%]
评估肾细胞癌患者辅助治疗疗效：SWOG S0931（EVEREST）III期试验中的药代动力学分析结果(NCT01120249)
Timothy W Synold,Melissa Plets,Catherine M Tangen et al.
Timothy W Synold et al.
Background: S0931 is assessing recurrence-free survival in renal cell carcinoma (RCC) patients randomized to receive everolimus (EVE) versus placebo for one year following nephrectomy. Due to a higher than expected dropou...
Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048 [0.03%]
trebananib(AMG386)联合或不联合继续抗血管内皮生长因子治疗在贝伐单抗、帕唑帕尼、索拉非尼或舒尼替尼进展的肾细胞癌患者中的2期随机研究——美国国家癌症研究所/癌症治疗评价计划9048方案结果
Thomas J Semrad,Susan Groshen,Chunqiao Luo et al.
Thomas J Semrad et al.
Background: In renal cell carcinoma (RCC), angiopoietin (Ang) 2 is elevated at the time of progression on anti-vascular endothelial growth factor (VEGF) therapy and may contribute to resistance. ...
The 'Achilles Heel' of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy [0.03%]
肾细胞癌的代谢“阿喀琉斯之踵”：谷氨酰胺酶抑制作为合理的治疗策略
Christian R Hoerner,Viola J Chen,Alice C Fan
Christian R Hoerner
An important hallmark of cancer is 'metabolic reprogramming' or the rewiring of cellular metabolism to support rapid cell proliferation [1-5]. Metabolic reprogramming through oncometabolite-mediated transformation or activation of oncogenes...
What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial [0.03%]
索拉非尼辅助治疗术后中高危肾细胞癌患者需获得多少生存收益才具成本效力度？SORCE试验临床研究者的偏好分析
Nicola J Lawrence,Andrew Martin,Ian D Davis et al.
Nicola J Lawrence et al.
Background: Decisions about adjuvant therapy involve trade-offs between possible benefits and harms. Objective: We sought to determine ...
Tim J van Oostenbrugge,Jurgen J Fütterer,Peter F A Mulders
Tim J van Oostenbrugge
The prognosis of renal tumors depends on histologic subtype. The increased use of abdominal imaging has resulted in an increase in the number of small renal incidentaloma in recent decades. Of these incidentally discovered tumors, 20% are b...
Perioperative Statin Use and Acute Kidney Injury in Patients Undergoing Partial Nephrectomy [0.03%]
经皮肾部分切除术患者围手术期他汀类药物的使用与急性肾损伤的关系
Shreyas S Joshi,Karen Ruth,Marc C Smaldone et al.
Shreyas S Joshi et al.
Background: Statin use is widespread among the general population. Data suggest a potentially beneficial effect of statin therapy on renal function following surgery. The impact of statins on post-partial nephrectomy (PN)...
The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013-2016 from the ClinicalTrials.gov Website [0.03%]
2013至2016年肾细胞癌临床试验的发展状况报告（来源于ClinicalTrials.gov网站）
Pooja Ghatalia,Rebecca Koenigsberg,David Pisarcik et al.
Pooja Ghatalia et al.
Background: We previously published an analysis of clinical trials in renal cell carcinoma (RCC) using the publicly available ClinicalTrials.gov registry. Here we present a 3-year update to understand clinical research cu...
Tissue Expression of Erythropoietin Predicts Survival Rates in Clear Cell Renal Cell Carcinoma [0.03%]
红细胞生成素组织表达可预测透明细胞肾细胞癌患者的生存率
Daniel Beltrame Ferreira,Walter Henriques da Costa,Diego Abreu Clavijo et al.
Daniel Beltrame Ferreira et al.
Objective: To evaluate immunohistochemical erythropoietin (EPO) expression in clear cell renal cell carcinoma (ccRCC), its association with major clinicopathological variables and its prognostic impact. ...
Moshe C Ornstein,Jorge A Garcia
Moshe C Ornstein
Background: Checkpoint inhibitors (CPI) have now been established as standard agents in the management of patients with metastatic renal cell carcinoma (mRCC). Given the unique toxicity profiles of CPIs, a detailed unders...